NCT04511481 is a clinical trial of Radiomic Algorithm in Predictive Cancer Model, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Who is sponsoring NCT04511481?

NCT04511481 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

What drugs are being tested in NCT04511481?

Interventions in NCT04511481: Radiomic Algorithm.

What condition does NCT04511481 study?

NCT04511481 studies Predictive Cancer Model.

Is NCT04511481 still recruiting?

NCT04511481 is currently status unknown. Last updated 13 August 2020.

Last reviewed 2020-08-13 · How we verify

NCT04511481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep Learning Magnetic Resonance Imaging Radiomic Predict Platinum-sensitive in Patients With Epithelial Ovarian Cancer

Status unknown Last updated 13 August 2020

What this trial tests

trial testing Radiomic Algorithm in Predictive Cancer Model in 93 participants. Status unknown.

Timeline

15 April 2020

Primary endpoint
3 August 2020

1 January 2021

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	93
Start date	15 April 2020
Primary completion	3 August 2020
Estimated completion	1 January 2021
Sites	1 location across China

Drugs / interventions tested

Radiomic Algorithm

Conditions studied

Predictive Cancer Model — all drugs for Predictive Cancer Model →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 22 to 99, female only, with Predictive Cancer Model. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Platinum-sensitive is an important basis for the treatment of recurrent epithelial ovarian cancer (EOC) without effective methods to predict.We aimed to develop and validate the EOC deep learning system to predict the platinum-sensitive of EOC patients through analysis of enhanced magnetic resonance imaging (MRI) images before initial treatment.Ninety-three EOC patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery from Sun Yat-sen Memorial Hospitalin China from January 2011 to January 2020 were enrolled. This deep-learning EOC signature achieved a high predictive power for platinum-sensitive, and the signature based on MRI whole volume is better than that on primary tumor area only.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Deep learning magnetic resonance imaging predicts platinum sensitivity in patients with epithelial ovarian cancer.
Lei R, Yu Y, Li Q, Yao Q, et al · · 2022 · cited 9× · PMID 36505880 · DOI 10.3389/fonc.2022.895177

Verify or expand the search:

Other trials of Radiomic Algorithm

Trials testing the same drug.

NCT05179850 — Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children · unknown
NCT05170282 — Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants · unknown
NCT04452058 — CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC · unknown

Other recruiting trials for Predictive Cancer Model

Currently open trials in the same condition.

NCT06364371 — Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer · recruiting
NCT06391892 — Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery · Phase 3 · recruiting
NCT06140823 — Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models · active not recruiting
NCT05929365 — Innovative Approach to Detect Recurrent Colorectal Lesions With Surveillance Via Mutation Analysis & Clinical Phenotype · recruiting
NCT05741944 — The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients · NA · active not recruiting

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04511481 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Last refreshed: 13 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04511481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing